JP Morgan Cazenove and Morgan Stanley were global coordinators on the sale of a 7.7% stake in the UK consumer healthcare ...

Pfizer Inc. (NYSE:PFE) has announced the sale of shares worth £2.50 billion ($3.05 billion) in British consumer healthcare ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

Pfizer will sell shares worth £2.50 billion ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.

The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

Haleon PLC has completed the acquisition of an additional 33% equity interest in its China-based joint venture, Tianjin TSKF Pharmaceutical Co. Ltd, for approximately £0.5 billion. This move ...

Recent restructuring efforts, including the spin-off of its consumer health business Haleon, have allowed the board to refocus on its core pharmaceuticals and vaccine operations. GSK’s pipeline ...

Jemperli is central to GSK’s immuno-oncology research and development efforts. Credit: GSK. GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) ...

The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK (LSE: GSK). GSK is partnering with Relation to discover new targets for fibrotic ...